

20 May 2026

## **Dermatology biologic drugs**

**Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:**

- Adalimumab – Humira 32
- Adalimumab Biosimilar 287
- Apremilast – Otezla <5
- Apremilast generic 0
- Bimekizumab 16
- Brodalumab 0
- Certolizumab 8
- Deucravacitinib <5
- Dimethyl fumarate 0
- Etanercept – Enbrel 0
- Etanercept Biosimilar <5
- Guselkumab 91
- Infliximab – Remicade <5
- Infliximab Biosimilar 14
- Ixekizumab 68
- Risankizumab 110
- Secukinumab 66
- Tildrakizumab <5
- Ustekinumab – Stelara <5
- Ustekinumab Biosimilar 98
- Omalizumab 37
- Spesolimab 0

**Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:**

- Adalimumab – Humira 10
- Adalimumab Biosimilar 45
- Bimekizumab <5
- Certolizumab 0
- Infliximab – Remicade 0
- Infliximab Biosimilar 9
- Secukinumab 16
- Ustekinumab – Stelara 0
- Ustekinumab Biosimilar <5

**20 May 2026**

Some figures have been withheld and replaced with less than five (<5). This is because disclosure of small numbers may risk identifying individuals. The information is therefore exempt under Section 40(2) of the Freedom of Information Act 2000 - Personal Information relating to a third party. Its release would contravene the data protection principles set out in the UK GDPR.